» Articles » PMID: 36329260

Oxalate Homeostasis

Overview
Journal Nat Rev Nephrol
Specialty Nephrology
Date 2022 Nov 4
PMID 36329260
Authors
Affiliations
Soon will be listed here.
Abstract

Oxalate homeostasis is maintained through a delicate balance between endogenous sources, exogenous supply and excretion from the body. Novel studies have shed light on the essential roles of metabolic pathways, the microbiome, epithelial oxalate transporters, and adequate oxalate excretion to maintain oxalate homeostasis. In patients with primary or secondary hyperoxaluria, nephrolithiasis, acute or chronic oxalate nephropathy, or chronic kidney disease irrespective of aetiology, one or more of these elements are disrupted. The consequent impairment in oxalate homeostasis can trigger localized and systemic inflammation, progressive kidney disease and cardiovascular complications, including sudden cardiac death. Although kidney replacement therapy is the standard method for controlling elevated plasma oxalate concentrations in patients with kidney failure requiring dialysis, more research is needed to define effective elimination strategies at earlier stages of kidney disease. Beyond well-known interventions (such as dietary modifications), novel therapeutics (such as small interfering RNA gene silencers, recombinant oxalate-degrading enzymes and oxalate-degrading bacterial strains) hold promise to improve the outlook of patients with oxalate-related diseases. In addition, experimental evidence suggests that anti-inflammatory medications might represent another approach to mitigating or resolving oxalate-induced conditions.

Citing Articles

OxDc-A0: an oral gastro-tolerant oxalate decarboxylase for treating secondary hyperoxaluria.

Liu H, Li C, Liu Y, Yao Q, Li Q, Yu L Urolithiasis. 2025; 53(1):47.

PMID: 40044966 DOI: 10.1007/s00240-025-01698-0.


Gut microbiota modulation via fecal microbiota transplantation mitigates hyperoxaluria and calcium oxalate crystal depositions induced by high oxalate diet.

An L, Li S, Chang Z, Lei M, He Z, Xu P Gut Microbes. 2025; 17(1):2457490.

PMID: 39873191 PMC: 11776474. DOI: 10.1080/19490976.2025.2457490.


Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.

Cellini B, Baum M, Frishberg Y, Groothoff J, Harris P, Hulton S Kidney Int Rep. 2024; 9(11):3083-3096.

PMID: 39534212 PMC: 11551133. DOI: 10.1016/j.ekir.2024.08.031.


Causal effects of specific gut microbiota on spinal stenosis diseases: a two-sample mendelian randomization study.

Luo K, Zeng W, Li Q, Zhang Y, Liu S, Liu X Front Genet. 2024; 15:1400847.

PMID: 39399222 PMC: 11467959. DOI: 10.3389/fgene.2024.1400847.


Role of Z-DNA Binding Protein 1 Sensing Mitochondrial Z-DNA and Triggering Necroptosis in Oxalate-Induced Acute Kidney Injury.

Chen C, Xie J, Chen Z, Ye K, Wu C, Dai X J Am Soc Nephrol. 2024; 36(3):361-377.

PMID: 39374087 PMC: 11888962. DOI: 10.1681/ASN.0000000516.


References
1.
Lange J, Wood K, Knight J, Assimos D, Holmes R . Glyoxal formation and its role in endogenous oxalate synthesis. Adv Urol. 2012; 2012:819202. PMC: 3332067. DOI: 10.1155/2012/819202. View

2.
Mehra Y, Viswanathan P . High-quality whole-genome sequence analysis of Lactobacillus paragasseri UBLG-36 reveals oxalate-degrading potential of the strain. PLoS One. 2021; 16(11):e0260116. PMC: 8604369. DOI: 10.1371/journal.pone.0260116. View

3.
Hautmann R, Osswald H . Pharmacokinetic studies of oxalate in man. Invest Urol. 1979; 16(5):395-8. View

4.
Aagaard L, Rossi J . RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007; 59(2-3):75-86. PMC: 1978219. DOI: 10.1016/j.addr.2007.03.005. View

5.
Waikar S, Srivastava A, Palsson R, Shafi T, Hsu C, Sharma K . Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression. JAMA Intern Med. 2019; 179(4):542-551. PMC: 6450310. DOI: 10.1001/jamainternmed.2018.7980. View